Literature DB >> 21411757

Down-regulation of BLIMP1α by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas.

Katerina Vrzalikova1, Martina Vockerodt, Sarah Leonard, Andrew Bell, Wenbin Wei, Alexandra Schrader, Kenneth L Wright, Dieter Kube, Martin Rowe, Ciaran B Woodman, Paul G Murray.   

Abstract

An important pathogenic event in Epstein-Barr virus (EBV)-associated lymphomas is the suppression of virus replication, which would otherwise lead to cell death. Because virus replication in B cells is intimately linked to their differentiation toward plasma cells, we asked whether the physiologic signals that drive normal B-cell differentiation are absent in EBV-transformed cells. We focused on BLIMP1α, a transcription factor that is required for plasma cell differentiation and that is inactivated in diffuse large B-cell lymphomas. We show that BLIMP1α expression is down-regulated after EBV infection of primary germinal center B cells and that the EBV oncogene, latent membrane protein-1 (LMP-1), is alone capable of inducing this down-regulation in these cells. Furthermore, the down-regulation of BLIMP1α by LMP-1 was accompanied by a partial disruption of the BLIMP1α transcriptional program, including the aberrant induction of MYC, the repression of which is required for terminal differentiation. Finally, we show that the ectopic expression of BLIMP1α in EBV-transformed cells can induce the viral lytic cycle. Our results suggest that LMP-1 expression in progenitor germinal center B cells could contribute to the pathogenesis of EBV-associated lymphomas by down-regulating BLIMP1α, in turn preventing plasma cell differentiation and induction of the viral lytic cycle.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21411757      PMCID: PMC3293751          DOI: 10.1182/blood-2010-09-307710

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  Epstein-Barr virus (EBV) infection in infectious mononucleosis: virus latency, replication and phenotype of EBV-infected cells.

Authors:  G Niedobitek; A Agathanggelou; H Herbst; L Whitehead; D H Wright; L S Young
Journal:  J Pathol       Date:  1997-06       Impact factor: 7.996

2.  Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo.

Authors:  Lauri L Laichalk; David A Thorley-Lawson
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  Significance of PRDM1beta expression as a prognostic marker in diffuse large B-cell lymphomas.

Authors:  Wayne Tam; Mario Gomez; Kui Nie
Journal:  Blood       Date:  2008-02-15       Impact factor: 22.113

4.  Generation of memory B cells and plasma cells in vitro.

Authors:  C Arpin; J Déchanet; C Van Kooten; P Merville; G Grouard; F Brière; J Banchereau; Y J Liu
Journal:  Science       Date:  1995-05-05       Impact factor: 47.728

5.  Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA.

Authors:  J Countryman; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

6.  Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen.

Authors:  G J Hoffman; S G Lazarowitz; S D Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

Review 7.  Epstein-Barr virus: 40 years on.

Authors:  Lawrence S Young; Alan B Rickinson
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

8.  Blimp-1-dependent repression of Pax-5 is required for differentiation of B cells to immunoglobulin M-secreting plasma cells.

Authors:  Kuo-I Lin; Cristina Angelin-Duclos; Tracy C Kuo; Kathryn Calame
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

9.  Epstein-Barr virus infection leads to partial phenotypic reversion of terminally differentiated malignant B cells.

Authors:  Eleni Anastasiadou; Signe Vaeth; Laura Cuomo; Francesco Boccellato; Sara Vincenti; Mara Cirone; Carlo Presutti; Steffen Junker; Gösta Winberg; Luigi Frati; Paul A Wade; Alberto Faggioni; Pankaj Trivedi
Journal:  Cancer Lett       Date:  2009-05-28       Impact factor: 8.679

10.  Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia.

Authors:  L S Young; R Lau; M Rowe; G Niedobitek; G Packham; F Shanahan; D T Rowe; D Greenspan; J S Greenspan; A B Rickinson; P J Farrell
Journal:  J Virol       Date:  1991-06       Impact factor: 6.549

View more
  43 in total

Review 1.  EBV-associated lymphomas in adults.

Authors:  Mark Roschewski; Wyndham H Wilson
Journal:  Best Pract Res Clin Haematol       Date:  2012-02-05       Impact factor: 3.020

2.  Functional interplay of Epstein-Barr virus oncoproteins in a mouse model of B cell lymphomagenesis.

Authors:  Thomas Sommermann; Tomoharu Yasuda; Jonathan Ronen; Tristan Wirtz; Timm Weber; Ulrike Sack; Rebecca Caeser; Jingwei Zhang; Xun Li; Van Trung Chu; Anna Jauch; Kristian Unger; Daniel J Hodson; Altuna Akalin; Klaus Rajewsky
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-10       Impact factor: 11.205

3.  Epstein-Barr virus (EBV) provides survival factors to EBV+ diffuse large B-cell lymphoma (DLBCL) lines and modulates cytokine induced specific chemotaxis in EBV+  DLBCL.

Authors:  Liang Wu; Barbro Ehlin-Henriksson; Xiaoying Zhou; Hong Zhu; Ingemar Ernberg; Lorand L Kis; George Klein
Journal:  Immunology       Date:  2017-08-11       Impact factor: 7.397

4.  Kaposi's sarcoma-associated herpesvirus oncoprotein K13 protects against B cell receptor-induced growth arrest and apoptosis through NF-κB activation.

Authors:  Ciaren Graham; Hittu Matta; Yanqiang Yang; Han Yi; Yulan Suo; Bhairavi Tolani; Preet M Chaudhary
Journal:  J Virol       Date:  2012-12-12       Impact factor: 5.103

5.  The B-cell-specific transcription factor and master regulator Pax5 promotes Epstein-Barr virus latency by negatively regulating the viral immediate early protein BZLF1.

Authors:  Ryan M Raver; Amanda R Panfil; Stacy R Hagemeier; Shannon C Kenney
Journal:  J Virol       Date:  2013-05-15       Impact factor: 5.103

6.  Latent Membrane Protein 1 (LMP1) and LMP2A Collaborate To Promote Epstein-Barr Virus-Induced B Cell Lymphomas in a Cord Blood-Humanized Mouse Model but Are Not Essential.

Authors:  Shi-Dong Ma; Ming-Han Tsai; James C Romero-Masters; Erik A Ranheim; Shane M Huebner; Jillian A Bristol; Henri-Jacques Delecluse; Shannon C Kenney
Journal:  J Virol       Date:  2017-03-13       Impact factor: 5.103

Review 7.  Regulation of the latent-lytic switch in Epstein-Barr virus.

Authors:  Shannon C Kenney; Janet E Mertz
Journal:  Semin Cancer Biol       Date:  2014-01-20       Impact factor: 15.707

8.  Epstein-Barr virus utilizes Ikaros in regulating its latent-lytic switch in B cells.

Authors:  Tawin Iempridee; Jessica A Reusch; Andrew Riching; Eric C Johannsen; Sinisa Dovat; Shannon C Kenney; Janet E Mertz
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

9.  Selective expression of the transcription elongation factor ELL3 in B cells prior to ELL2 drives proliferation and survival.

Authors:  Lou-Ella M M Alexander; January Watters; Jessica A Reusch; Michelle Maurin; Brook S Nepon-Sixt; Katerina Vrzalikova; Mark G Alexandrow; Paul G Murray; Kenneth L Wright
Journal:  Mol Immunol       Date:  2017-08-31       Impact factor: 4.407

10.  Activation of the B cell antigen receptor triggers reactivation of latent Kaposi's sarcoma-associated herpesvirus in B cells.

Authors:  Semra Kati; Edward H Tsao; Thomas Günther; Magdalena Weidner-Glunde; Thomas Rothämel; Adam Grundhoff; Paul Kellam; Thomas F Schulz
Journal:  J Virol       Date:  2013-05-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.